首页> 外文期刊>Blood: The Journal of the American Society of Hematology >CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo
【24h】

CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo

机译:CEACAM2在体内和体外对半(含ITAM的)GPVI和CLEC-2途径及血栓生长负调节

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Carcinoembryonic antigen-related cell adhesion molecule-2 (CEACAM2) is a cell-surface glycoprotein expressed on blood, epithelial, and vascular cells. CEACAM2 possesses adhesive and signaling properties mediated by immunoreceptor tyrosine-based inhibitory motifs. In this study, we demonstrate that CEACAM2 is expressed on the surface and in intracellular pools of platelets. Functional studies of platelets from Ceacam2-/--deficient mice (Cc2-/-) revealed that CEACAM2 serves to negatively regulate collagen glycoprotein VI (platelet) (GPVI)-FcRγ-chain and the C-type lectinlike receptor 2 (CLEC-2) signaling. Cc2-/-platelets displayed enhanced GPVI and CLEC-2-selective ligands, collagen-related peptide (CRP), collagen, and rhodocytin (Rhod)-mediated platelet aggregation. They also exhibited increased adhesion on type I collagen, and hyperresponsive CRP and CLEC-2-induced a and dense granule release compared with wild-type platelets. Furthermore, using intravital microscopy to ferric chloride (FeCl3)-injured mesenteric arterioles and laser-induced injury of cremaster muscle arterioles, we herein show that thrombi formed in Cc2-/-mice were larger and more stable than wild-type controls in vivo. Thus, CEACAM2 is a novel platelet immunoreceptor that acts as a negative regulator of platelet GPVI-collagen interactions and of ITAM receptor CLEC-2 pathways.
机译:癌胚抗原相关细胞粘附分子2(CEACAM2)是在血液,上皮和血管细胞上表达的细胞表面糖蛋白。 CEACAM2具有基于免疫受体酪氨酸的抑制性基序介导的粘附和信号传导特性。在这项研究中,我们证明CEACAM2在血小板的表面和细胞内池中表达。来自Ceacam2-/-缺陷小鼠(Cc2-/-)的血小板功能研究表明,CEACAM2可负调节胶原糖蛋白VI(血小板)(GPVI)-FcRγ链和C型凝集素样受体2(CLEC-2) )信令。 Cc2-/-血小板显示出增强的GPVI和CLEC-2-选择性配体,胶原蛋白相关肽(CRP),胶原蛋白和杜鹃素(Rhod)介导的血小板凝集。与野生型血小板相比,它们还表现出对I型胶原的粘附增加,以及高反应性CRP和CLEC-2诱导的α和致密颗粒释放。此外,使用活体显微镜检查氯化铁(FeCl3)损伤的肠系膜小动脉和激光诱导的提睾肌小动脉损伤,我们在本文中显示,Cc2-/-小鼠体内形成的血栓比体内的野生型对照更大,更稳定。因此,CEACAM2是一种新型的血小板免疫受体,可作为血小板GPVI-胶原相互作用和ITAM受体CLEC-2途径的负调节剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号